RedHill Biopharma erhält von der amerikanischen Zulassungsbehörde (FDA) den Fast-Track-Status für RHB-204 bei einer Erkrankung mit NTM - Seite 4

^[3] Kim RD, et al. Pulmonary Nontuberculous Mycobacterial Disease. Prospective Study of a Distinct Preexisting Syndrome Am J Respir Crit Care Med. 2008; 178(10):1066–74.

^[4] The American Lung Association, 2020.

^[5] Henkle E, et al. Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012 Annals of the American Thoracic Society. 2015; 12(5):642-7.

^[6] Foster|Rosenblatt, 2017.

^[7] Griffith DE, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med. 2007;175(4):367-416.

^[8] Prevots DR et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010; 182:970-76; Winthrop KL, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010; 182: 977-82

^[9] Full prescribing information for Movantik (naloxegol) is available at: www.Movantik.com. 

^[10] Full prescribing information for Talicia (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.    

^[11] Full prescribing information for Aemcolo (rifamycin) is available at: www.Aemcolo.com. 

Logo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg 

Unternehmenskontakt:  Adi Frish Chief Corporate & Business Development Officer RedHill Biopharma [phone] [e-mail]

Kontakt für Medienvertreter (USA):  Bryan Gibbs Vice President Finn Partners [phone] [e-mail]